Состояние костной системы и фосфорно-кальциевого обмена у больных тиреотоксикозом в условиях йодного дефицита, влияние адекватной терапии
Диссертация
Прогрессирующая распространенность остеопороза и связанных с ним переломов костей скелета в популяции делает эту проблему одной из наиболее важных для современной медицины. По имеющимся сведениям около 200 миллионов людей в мире страдают остеопорозом (Любимова Н.В., 1997; Михайлов Е. Е., Беневоленская Л. И., 2003; Peaston R., 1997; Kanis J.A., 1999). Исследования ряда авторов свидетельствуют… Читать ещё >
Содержание
- Список сокращений
- Глава 1. Обзор литературы
- 1. 1. Влияние тиреоидных гормонов на костную ткань в норме и при патологии
- 1. 2. Тиреотоксикоз (субклинический и клинический) и его влияние на состояние костной ткани
- 1. 3. Профилактика и лечение костных поражений при субклиническом и манифестном тиреотоксикозе
- Глава 2. Характеристика обследованных больных и методов исследования
- 2. 1. Характеристика больных тиреотоксикозом осложненным остеопенией и остеопорозом в условиях йодного дефицита
- 2. 2. Характеристика методов исследования
- 2. 3. Статистические методы исследования
- Глава 3. Результаты исследования
- 3. 1. Исследование минеральной плотности костной ткани у больных тиреотоксикозом в условиях йодного дефицита
- 3. 2. Исследование показателей кальций-фосфорного обмена, костного метаболизма у больных тиреотоксикозом в условиях йодного дефицита
3.3. Влияние дифференцированной терапии препаратами кальция и бисфосфонатами на фоне достигнутого эутиреоидного состояния в профилактике и лечении остеопенического синдрома при тиреотоксикозе в условиях йодного дефицита.
Глава IV. Обсуждение полученных результатов.
Выводы.
Список литературы
- Аникин, Г. Ретроспективное исследование факторов риска переломов бедра у женщин / Г. Аникин // Остеопороз и остеопатии. 2001. — № 1. — С. 2−4.
- Анварова Ш. С. Материалы семинара — Йоддефицитные состояния и профилактика зоба. — Душанбе, 1996.- С. 1−13.
- Белая, Ж.Е. Ибадронат (Бонвива) новое направление в лечении бисфосфонатами. Лучшая приверженность к лечению — лучший результат /Л.Я.Рожинская, Г. А. Мельниченко // Ж. Остеопороз и остеопатии. — 2006. -№ 3. — С.23−29.
- Болезни органов эндокринной системы / Под ред. И. И. Дедова. М.: Медицина, 2000.-294с.
- Болезни щитовидной железы / Под ред. Бравермана. М.: Медицина, 2000 С.203−205.
- Вербовая, М. В. Минеральная плотность костной ткани, показатели ее метаболизма и кальций-фосфорного обмена у больных тиреотоксикозом / М. В. Вербовая // Остеопороз и остеопатии. 2002. — № 1. — С. 16−19.
- Власова, И. Изменение минеральной плотности костной ткани у пациентов с тиреотоксикозом / И. Власова, Т. Ю. Беркетова, Г. А. Мельниченко // Пробл. эндокринол. 2003. — № 3. — С.9−14.
- Влияние манифестного и субклинического тиреотоксикоза на костную систему взрослых /Ж. Е. Белая, Л .Я. Рожинская, Г. А. Мельниченко // Пробл. эндокринол. 2007. — Т.53, № 2. — С. 9−15.
- Гарбузов, П. И. Алгоритмы диагностики и лечения высокодифференцированного рака щитовидной железы / П. И. Гарбузов // Ж. Клиническая тиреоидология. 2003. — том 1. — № 3. — С. 27−31.
- Дедов И.И. Первичный и вторичный остеопороз: патогенез, диагностика, принципы профилактики и лечения/ И. И. Дедов, Л. Я. Рожинская, Е. И. Марова // Методическое пособие для врачей. Москва. — 1999.
- Динамика минеральной плотности костной ткани (МПКТ) у женщин до и после оперативного лечения по поводу диффузного токсического зоба (ДТЗ) / J1.B. Сипина, Е. И. Марова, Н. С. Кузнецова и др. // Остеопороз и остеопатии. 2002. — № 2. — С.10−12.
- Ермакова, И. П. Современные биохимические маркеры в диагностике остеопороза / И. П. Ермакова, И. А. Пронченко // Остеопороз и остеопатии. -1998.-№ 1.-С.24−27.
- Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение / Под ред. Л. И. Беневоленской, О. М. Лесняк. М.: ГЭОТАР-Медиа, 2008.- 176с.
- Костная денситометрия в диагностики мониторинге остеопатии / И. И. Дедов, Т. О. Чернова, О. Р. Григорян и др. // Остеопороз и остеопатии. -2000.-№ 3.-С.16−19.
- Мельниченко Г. А. Эндокринология: типичные ошибки практического врача / Г. А. Мельниченко, О. В. Удовиченко, А. Е. Шведова. // М.: Практическая медицина. 2011. — 176с.
- Михайлов, Е. Е. Частота переломов проксимального отдела бээедренной кости и дистального отдела предплечья среди городского населения России / Е. Е. Михайлов, Л. И. Беневоленская, Г. Аникин // Остеопороз и остеопатии. -1999.-№ 3.-С. 2−6.
- Оганов, В. Гипокинезия фактор риска остеопороза / В. Оганов // Остеопороз и остеопатии. — 1998. — № 1.- 13−17.
- Остеопороз / под ред. О. М. Лесняк, Л. И. Беневоленской. 2-е изд., перераб. и доп. — М.: ГЭОТАР-Медиа, 2009. — 272с.
- Оценка йодной недостаточности в отдельных регионах России / И. И. Дедов, Н. Ю. Свириденко, Б. П. Мищенко // Москва. 1998.
- Показатели кальций-фосфорного обмена и костного метаболизма у больных диффузным токсическим зобом / Н. К. Ахкубекова, Е. И. Марова, Л. Я. Рожинская и др. // Пробл. эндокринол. 1997. — Т. 43, № 5- С.12−16.
- Риггз, Б. Л. Остеопороз. Этиология, диагностика, лечение / Б. Л. Риггз, Л. Д. Мелтон: Пер. с англ. под ред. Е. А. Лепарского. СПб.: Бином, Невский диалект, 2000. — 558с.
- Рожинская, Л. Я. Остеопенический синдром при заболеваниях эндокринной системы и постменопаузальный остеопороз (патогенетические аспекты, диагностика и лечение): Автореф. дис.. д-ра мед. наук /Л. Я. Рожинская. М.- 2001. — 86с.
- Рожинская, Л. Я. Системный остеопороз. Практ. рук. для врачей / Л. Я. Рожинская. 2-е изд., перераб. и доп. — М.: Издатель Мокеев, 2000. — 195 с.
- Руководство по остеопорозу / Под ред. Л. И. Беневоленской. М.: БИНОМ. Лаборатория знаний, 2003. — 524 с.
- Фадеев В.В. Диагностика и лечение токсического зоба. / В. В. Фадеев. -РМЖ, 2002.- 10(11). С.513−516.
- Цыган, Е.Н. Морфофункциональные основы остеопороза / Е. Н. Цыган, Р. В. Деев. СПб.: ВМедА, 2007. — 120 с.
- Щеголева, О.А. Минеральная плотность костной ткани и факторы риска развития остеопороза у женщин с нарушениями функции щитовидной железы: Автореф. дис.. канд. мед. наук: 14.00.05 / О. А. Щеголова. -Иркутск, 2005, 22с.
- Шварц, Г. Я. Фармакотерапия остеопороза / Г. Я. Шварц. -М.: Медицинское информационное агентство. 2002. — 368 с.
- Эндокринология / Пер. с англ. под ред. Н. Лавина. М.: Практика, 1999.1128 с.
- ААСЕ Thyroid Task Force. American Association of Clinical Endocrinilogist medical guidelines for clinical practice for the evaluation and treatment of thyperthyroidism and hypothyroidism / Endocr. Pract. 2002. — V. 8(6). — P. 457 469.
- Aaron, J. The microanatomy of trabecular bone loss in normal aging men and women / J. Aaron, N. Makins, K. Sagreiya // Clin. Orthop. 1987. — Vol. 15. -P.260−271.
- A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women / T. Boonya-Ussadorn, B. Punkaew, N. Sriassawaamorn // J Med Assoc Thai. 2010. — Vol. 93. — p. 1−5.
- Acotto C.G. Ultrasound parametrs and markers of bone turnover in hyperthyroidism: a longitudinal study / C.G.Acotto, H. Niepomniszcze, E. Vega et al. // J. Clin. Densit. 2004. — Vol. 7. — P. 201−208.
- Aghini-Lombardi, F. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey./ F. Aghini-Lombardi, L. Antonanceli, E. Martino et al. // J. Clinic. Endocrin. Metab. 1999. — Vol. 84. — P. 561−566.
- Age, time since menopause and body parameters as determinants of female spinal bone mass: a mathematical modal / C. Trevisan, S. Ortolani, M. Bianchi et al. // Calcif. Tissue Int. 1991. — Vol. 49. — P. 1−5.
- A longitudinal study of markers of bone turnover in Graves disease and their value in predicting bone mineral density / A. Siddigi, J. Burrin, K. Noonan et al. // .// J. Clin. Endocrinol. Metab. 1997. — Vol. 82. — P. 753−759.
- Amato, G. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment / G. Amato, G. Mazziotti, F. Sorvillo et al. // J. Bone. 2004. — Vol. 35. — P. 785−791.
- Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism / E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez et al.// J. Clin. Endocrinol. Metab. 1997. — Vol. 82. — P. 1989−1994.
- Arata, N. Bone mineral density after surgical treatment for Graves disease / N. Arata, N. Momotani, H. Maruyama et al. // J. Thyroid. 1997. — Vol. 7. — P. 547 554.
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group / WHO Tech. Report Series. 1994. -843 p.
- Bagger, Y.Z. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? / Y.Z. Bagger, H.B. Rasmussen, P. Alexandersen et al. // J. Osteoporosis International. 2007. — Vol. 18. -P. 505−512.
- Baker, J.C. Harland R.M. From receptor to nucleus: the Smad pathway / J.C. Baker, R.M. Harland // J. Current Opinion in Genetics and Development. 1997. -Vol. 7. — P. 467−473.
- Baran, D. Thyroid hormone and bone mass / D. Baran, L. Braverman // J. Clin. Endocrinol. Metab. 1991. -Vol. 72. — P. 1182−1183.
- Baran, D. Thyroid hormone and bone mass. The clinicians dilemma / D. Baran // Thyroid. 1994. — Vol. 4. — P. 143−144.
- Barsal, G. Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy / G. Barsal, F. Taneli, A. Atay et al. // Tohoku J. Experiment. Medicine. 2004. — Vol. 203. — P. 183−188.
- Bassett, J. H. D. The molecular actions of thyroid hormone in bone / J. H. D. Bassett, G.R. Williams // Trends in Endocrinology and Metabolism 2003. Vol. 14. — P. 356−364
- Bauer, D.C. Risk for fracture in women with low serum levels of thyroid-stimulating hormone / D.C. Bauer, B. Ettinger, M.C. Nevitt et al. // J. Annals Intern. Med. 2001. — Vol. 134. — P. 561−568.
- Bauer, D.C. Low thyrotropin levels are not associated with bone loss in older women: a prospective study / D.C.Bauer, M.C. Nevitt, B. Ettinger et al. // J. Clin. Endocrin. and Metab. 1997. — Vol. 82. — P. 2931−2936.
- Bauss, F. Ibadronate in osteoporosis: preclinical data and rationale for intermittent dosing / F. Bauss, R. Graham, G. Russell // J. Osteoporosis Intenat. -2004.-Vol. 15.-P. 423−433.
- Ben-Shlomo, A. Early postmenopausal bone loss in hyperthyroidism / A. Ben-Shlomo, P. Hagag, S. Evans et al. // J. Maturatis. 2001. — Vol. 39. — P. 19−27. 46
- Bianco, A.C. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronin selenodeiodinases / A.C. Bianco, D. Salvatore, B. J. Gereben et al. // Endocrin. Review. 2002. — Vol. 23. — P. 38−89.
- Biondi, B. Subclinical hyperthyroidism clinical features and treatment options / B. Biondi, E.A. Palmeri, Klain M, et al. // European J. Endocrinology. 2005. -Vol. 152. — P. 1 -9.
- Bjarnason, N.H. The effect of Fluvastatin in parameters of bone remodeling / N.H. Bjarnason, B. J. Riis, C. J. Christiansen // Osteop. Internat. 2001. — Vol. 12. -P. 380−384.
- Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of etiology and menopause / E. Jodar, M. Munoz-Torres. F. Escobar-Jimenez et al. // Clin. Endocrinol. 1997. — Vol. 47. -P.279−285.
- Bone loss in thyroid disease: role of low TSH and high thyroid hormone / E. Abe, L. Sun, J. Mechanick et al. // Ann N Y Acad Sci. 2007. — Vol. 1116. -P.383−91.
- Bone marker concentrations in postmenopausal female hypothyroid patients treated with thyroxine / A. Davy, J. Laycock, J. Jones et al. // J. Endocrinol. -1997.-Vol. 152.-P. 50.
- Bone markers: biochemical and clinical perspectives / R. Eastell, M. Bauman, N. Hoyle et al. Roche Martin Dunitz Ltd, 2001. — 252 p.
- Bone mass, bone turnover, calcium homeostasis and body composition in surgically and radioiodinetreated former hyperthyroid patients / B. Langdahl, A. 1 .oft, E. Eriksen et al.// Thyroid. 1996. — Vol. 6. — P. 169−175.
- Bone mass in females with different thyroid disorders: influence of menopausal status / M. M. Campos-Pastor, M. Munoz-Torres. F. Escobar-Jimenez et al.// Bone Miner.- 1993.-Vol.21.-P. 1−8.
- Bone mass in totally thyroidectomized patients / D. Gonzalez, C. Mautalen- P. Correa et al. // Acta Endocrinol. 1991. — V. 124. — P. 521−525.
- Bone metabolism in patient with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment / P. Mikosch, B. Obermayer-Pietsch, R. Jost et al. // Thyroid. 2002. — Vol. 13. — P. 347−356.
- Bone mineral after surgical treatment for Graves disease / A. Naoco, M. Naoco, H. Hiroshi et al. // Thyroid. 1997. — Vol. 7. — P. 547−554.
- Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy / M. Garton, I. Reid, N. Loveridge et al. // Clin. Endocrinol. 1994. — Vol. 41. — P. 747−755.
- Bone mineral density and thyroid hormone therapy / C. Ribot, F. Tremollieres, J. Pouilles et al. // Clin. Endocrinol. 1990. — Vol. 33. — P. 143−153.
- Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study / G. Saggese, S. Bertelloni, G. Baroncelli et al. // Eur. J. Pediat. -1996. Vol. 155. — P. 452−457.
- Bone mineral density in hyperthyroidism / Karga H., Papapetrou P.D., Korakovouni A. et al. // Clin. Endocrinol. 2004. — Vol. 61(4). — P.466−72.
- Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma / G. Gorres, A. Kaim, A. Otte et al. // Eur. J. Nucl. Med. 1996. — Vol. 23. — P. 690−692.
- Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma / C. M. Florkowski, B. E. Brownlie, J. R. Elliot et al. // N. Z. Med. J. 1993. — Vol. 106. — P. 443−444.
- Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? / J. Foldes, G. Tarjan, M. Szathmari et al. // Clin. Endocrinol. 1993. — Vol. 39. — P. 521−527.
- Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry / M. Wakasugi, R. Wakao, M. Tawata et al. // Clin. Endocrinol. 1993. — Vol. 38. — P. 283−286.
- Bone mineral density in postmenopausal women treated with L-thyroxine / E. V. Adlin, A. H. Mauer, A. D. Marks et al.// Am. J. Med. 1991. — Vol. 90. — P. 360 366.
- Bone mineral density in pre- and postmenopausal women with affective disorder treated with long-term L-thyroxine augmentation / L. Guilay, M. Bauer, F. Garcia-Espana et al. // J. Affect Disord. 2001. — V. 66. — P. 185−191.
- Bone mineral density in thyroxine treated females with or without a previous A history of thyrotoxicosis / J. Franklyn, J. Betteridge, R. Holder et al. // Clin. Endocrinol. 1994. -Vol. 41. — P. 425−432.
- Brown, J. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada / J. Brown, R. Josse // CMAJ. 2002. — V. 167. — P. 1−34.
- Campbell, J. Fine adjustment in thyroxine replacement- and its effect on bone metabolism / J. Campbell, P. Day, T. Diamond // Thyroid. 1996. — Vol. 6. — P. 75−78.
- Canaris G.J. The Colorado thyroid disease prevalence study / G.J. Canaris, N.R. Manowitz, G. Mayor et al. // J. Archives Internal Medicine. 2000. — Vol. 150.-P. 526−534.
- Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women / C. Marcocci, F. Golia, G. Bruno-Bossio et al. // J. Clin. Endocrinol. Metab. 1994. — Vol. 78. — P. 818−823.
- Caparevis, Z. Lipid abnormalities in elderly patients with subclinical hyperthyroidism / Z. Caparevis, D. Stojanovic, V. Ilic et al. // J. Med. preglad. -2003.-Vol. 56.-P. 564−567.
- Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry / M. Wkasugi, R. Wakao, M. Tawata et al. // Thyroid. 1994. — Vol.4. — P. 179−182.
- Chabaund O, Lissitzky S.: Thyrotropin-speciflc binding to human peripheral blood monocytes and polymorphonuclear leukocytes. J. Molecular Cellular Endocrinology, 1977, Vol. 7, pp. 79−87.
- Chen, C.H. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma / C.H. Chen, J.F. Chen, B.Y. Yang et al. // J. Form. Med. Ass. 2004. — Vol. 103. — P. 442−447.
- Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease / Majima T., Komatsu Y., Doi K. et al. // J. Bone and mineral metabolism. 2006. — Vol.24. — P. 105−113.
- Cloning and functional expression of a thyrotropin receptor cDNA from rat fat calls / T. Endo, K. Ohta, K. Haraguchi et al. // J. Biological Chemistry. 1995. -Vol. 270.-P. 10 833−10 837.
- Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture / S.P. Bours, T.A. van Geel, P.P. Geusens //J. Clin Endocrinol Metab. 2011. — Vol. 5. — p. 1360−1367.
- Costantini, F. Effect of thyroid function on LDL oxidation / F. Costantini, S.D.Pierdomenico, D. de Cesare et al. // J. Arteriosclerosis Thrombosis Vascular Biology. 1998. — Vol. 18. — P. 732−737.
- Cooper, D. Thoughts on prevention of thyroid disease in the United States / D. Cooper, E. Ridgway // Thyroid. 2002. — V. 12. — P. 925−929.
- Cooper M. S. Thyroid gland: Variation in 'normal' thyroid function—effect on bone health / M.S. Cooper // Nat Rev^ Endocrinol. 2010. — Vol. 11. — p. 599−600.
- Crisanti, P. The expression of thyrotropin receptor in the brain / P. Crisanti, B. Omri, E. Hughes et al. // J. Endocrinology. 2001. — Vol. 142. — P. 812−822
- Cummings S.R. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Group / S.R. Cummings M.C. Nevitt, W.S. Browner et al. // New England J. Medicine. 1995. — Vol. 332. — P. 767−773.
- Davies, T.F. Binding of thyroid stimulators to guinea pig testis and thyroid / T.F. Davies, B.R. Smith, R. Hall // J. Endocrinology. 1978. — Vol. 103. — P. 610
- Davies, T.F. Thyrotropin receptors in adipose tissue, retro-orbital tissue and lymphocytes / T.F. Davies, C.S. Teng, S.M. McLachlan et al. // J. Molecular Cellular Endocrinology. 1978. — Vol. 13. — P. 6−10
- Dennison, E. Determinants of bone loss in elderly men and women: a prospective study / E. Dennison, R. Eastell, G. Fall et al. // Osteoporos. Int. 1999. -Vol. 10.-P. 384−391.
- Dennison, E. Gooper G. Epidemiology of osteoporotic fractures / E. Dennison, G. Gooper // J. Hormone Research. 2000. — Vol. 54 (suppl 1). — P. 58−63.
- Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry / D. Baran, K. Faulkner, H. Genant et al. // Calcif. Tissue Int. -1997. -Vol.61.-P. 433−440.
- Diamond, T. Thyrotoxic bone disease in women: a potentially reversible disorder / T. Diamond, J. Vine, R. Smart et al. // J. Ann. Intern. Med. 1994. — Vol. 120.-P. 8−11.
- Differentiation of rat preadipocytes is accompanied by expression of thyrotropin receptors / K. Haraguchi, H. Shimura, L. Lin et al. // J. Endocrinology. 1996. — Vol. 137. — P. 3200−3205
- Discovering new hormones receptors and signaling mediators in the genomic era / S.Y. Hsu, A.J.W. Hsueh // J. Molecular Endocrinology. 2000. — Vol. 14. -P. 594−604
- Early postmenopausal bone loss in hyperthyroidism / A. Ben- Shlomo, P. Hagag, S. Evans et al. // Maturitas. 2001. — V. 39 (1). — P. 19−27.
- Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone / T.M. Galliford, E. Murphy, A.J. et al. // Minerva Endocrinol. 2005. — Vol. 30. P. 237−46.
- Edwards, C.J. Secondary contributors to bone loss in osteoporosis related hip fractures / B.J. Edwards, C.B. Langman, A.D. Bunta et al. // Osteoporos Int. -2008.-Vol. 19. P.991−999.
- Effect of calcitonin deficiency of bone density and bone turnover in totally thyroidectomized patients / P. Shneider, P. Berger, K. Knuse et al. // J. Endocrinol. Invest-199l.-V. 14.-P. 935−942.
- Effect of estrogen replacement therapy upon bone mineral density in thyroxine- treated postmenopausal women with a past history of thyrotoxicosis / J. A. Franklyn, J. Betteridge, R. Holder et al. // Thyroid. 1995. — Vol. 5. — P. 359−363.
- Effect of replacement doses of thyroxine on bone mineral density / A. W. Hanna, R. J. Pettit, F. Amman et al. // Clin. Endocrinol. 1998. — Vol. 48. — P. 229 234.
- Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism / P. Lecomte, N. Lecureuil, C. Osorio-Salazar et al. //Thyroid. -1995. -Vol. 5. P. 19−23.
- Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism / P. Affinito, C. Sorrentino, M. J. Farace et al. // Acta Obstet. Gynecol. Scand. 1996. — Vol. 75. — P.843−848.
- Effects on bone mass of long term treatment with thyroid hormones: a meta analysis / B. Uzzan, J. Campos, M. Cucherat et al. // J. Clin. Endocrinol. Metab. -1996.-Vol. 81. -P. 4278−4289.
- Eriksen, E. F. Kinetics of trabecular bone resorbtion and formation in A hypothyroidism. Evidence for a positive balance per remodeling cycle / E. F. Eriksen, L. Mosekilde, F. Melsen // Bone. 1986. — Vol. 7. — P. 101−108.
- Eriksen, E. F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease / E. F. Eriksen // Endocr. Rev. 1986. — Vol. 7. — P. 379−408.
- Eriksen, E. F. Trabecular bone remodeling and bone balance in hyperthyroidism / E. F. Eriksen, L. Mosekilde, F. Melsen // Bone. 1985. — Vol. 6. -P. 421−426.
- Escalante, D. Assessment of interchangeability of two brands of levothyroxine preparations with a third-generation TSH assay / D. Escalante, N. Arem, R. Arem // Am. J. Med. 1995. — Vol. 98. — P. 374−378.
- Evaluation of bone mineral density in hyperthyroid patients before and after medical therapy / Safi S., Hassikou H., Hadri L. et al.// J. Ann. Endocrinol. -2006.-Vol. 67.-P. 27−31.
- Evaluation of hip fracture risk score for assessing elderly women: The Melton Osteoporosis Fracture (MOF) Study / C. McGrother, M. Donaldson, D. Clayton et al. // Osteoporosis Int. 2002. — V. 13. — P. 89−96.
- Evidence for the presence of functional thyrothropin receptor in cardiac muscle / V. Drovota, A. Janson, C. Norman et al. // J. Bichemical Biophysical Researcg Communications. 1995.- Vol.211. — P. 426−231
- Faber, J. Changes in bone mass during prolonged subclinical hyperthyroidisn due to L-thyroxine treatment: a meta-analysis / J. Faber, A. M. Galloe // Eur. J. Endocrinol. 1994. — Vol. 130. — P. 350−356.
- Faber, J. Serum bone Gla-protein (BGP) during treatment of hyperthyroidism and hypothyroidism / J. Faber, H. Perrild, J. Johansen // Norm. Metab. Res. — 1991. — Vol. 23 .-P. 135−138.
- Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinicalhyperthyroidism / S. Buscemi, S. Verga, S. Cottone et al. // J Endocrinol Invest. 2007. Vol. 30. — P. 230−235.
- Felice, M. Minireview: Thyrotropin receptor signaling in development and differentiation of the thyroid gland: insights from mouse models and human diseases / Felice, M. Postiglione M P, Lauro R. // J. Endocrinology. 2004. — Vol. 145. — P. 4062−4067
- Forrest, D. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function
- D.Forrest, E. Hanebuth, RJ. Smeyne et al. // The European Molecular Biology Organization J. 1996. — Vol. 15. — P. 3006−3015.
- Fox, K. Loss of bone density and lean body mass after hip fracture / K. Fox, J. Magaziner, W. Hawkes // Osteoporosis Int. 2000. — V. 11.- P. 31−35.
- Fractures after thyroidectomy in men: a population-based cohort study / T. Nguyen, H. Heath 3d, S. Bryant et al. // J. Bone Miner. Res. 1997. — Vol. 12. -P. 1092−1099.
- Fractures following thyroidectomy in women. A population-based cohort study / Melton, E. Ardila, C Crowson et al. // Bone. 2000. — Vol. 27. — P. 595−700.
- Franklyn, J. The management of hyperthyroidism / J. Franklyn // N. Engl. J. Med. -1994.-V. 330.-P. 1731−1738.
- Garnero, P. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study / P. Garnero, E. Sornay-Rendu, B. Claustrat et al. // J. Bone Mineral Research. 2000. — Vol. 15. -P. 1526−1536.
- Gehrig, L. Osteoporosis: Managtment and Treatment Strategies for Orthopaedic Surgeons / L. Gehrig, J. Lane, M.I. O’Connor // J. Bone Joint Surg. Am. 2008. — Vol. 90. — P. 1362−1374.
- Greenspan, F. S. Basis and Clinical Endocrinology / F. S. Greenspan, D. G. Gardner // 7th Ed. New York, 2001. — P. 330−335
- Graves' disease and bone metabolism / K. Sato // Clin. Enocrinol. 2006. -Vol. 64.-p.2317−2322.
- Guo, C Y. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine / C Y. Guo, A. P. Weetman, R. Eastell // Clin. Enocrinol. 1997. — Vol. 46. — P. 301−307.
- Guadelines on the use of biochemical marcers of bone turnover in osteoporosis / Y. Nishizawa, T. Nakamura, H. Onata et al. // J. Bone Miner. Metab. -2001.-V. 19.-P. 338−344.
- Gurlek, A. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women / A. Gurlek, O. Gedic // J. Thyroid. 1999. — Vol. 9. — P. 539−543.
- Gu, W.X. Mutual up-regulation of thyroid hormone and parathyroid hormone receptors in rat osteoblastic osteosarcoma 17/2.8 cells / W.X.Gu, P.H. Stern, L.D. Madison et al. // J. Endocrinology. 2001. — Vol. 142. — P. 157−164
- Heemstra, K.A. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with welldifferentiated thyroid carcinoma / K.A. Heemstra, N.A. Hamdy, J.A. Romijn et al. // J. Thyroid. 2006. — Vol. 16. — P. 583−591.
- Helfand, M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the US Preventive Services Task Force / M. Helfand // J. Annual Internal Medicine. 2004. — Vol. 140. — P. 128−141.
- Hip fractures and the thyroid: a case-control study / B. Wejda, G. Hintze, B. Katschinski et al. // J. Intern. Med. 1995. — Vol. 237. — P. 241−247.
- Hofbauer L.C. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland / L.C. Hofbauer, S. Kluger, C.A. Kuhne et al. // J. Cellular Biochemestry. 2002. — Vol. 86. — P. 642−650.
- Horst-Sikorska^W. Association analysis of vitamin D receptor gene polymorphisms with bone mineral density in young women with Graves' disease / W. Horst-Sikorskai M. Marcinkowska, M. Kaczmarek et al. // Acta Biochim Pol. -2008. Vol.55.-P.371−380.
- Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study / A. Svare, T.I. Nilsen, T. Bjoro et al. // Eur, J. Endocrinol.- 2009. -Vol. 5. P. 779−786.
- Impaired cardiac reserve and exercise capacity in patient receiving long-term thyrotropin supressive therapy with levothyroxine / B. Biondi, S. Fazio, A. Cuocolo et al. // J. Clin. Endicrin. Metab. 1996. — V. 81. — P. 4701−4705.
- Inoue, M. Expression of thyrotropin receptor on clonal osteoblast-like rat osteosarcoma cells / M. Inoue, M. Tawata, N. Yokomori et al. // J. Thyroid. 1998. -Vol. 8. — P. 1059−1064
- Jamal, S.A. Clinical utility of laboratory testing in women with osteoporosis / S.A. Jamal, R.E. Leiter, A.M. Bayoumi et al. // J. Osteop. Intern. 2005. — Vol. 16. — P. 534−540.
- Johnell, O. An estimate of the world-wide prevalence and disability associated with osteoporotic fractures / O. Johnell, J.A. Kanis // J. Osteoporosis International. 2006. — Vol.17. — P. 1726−1733.
- Johnson, M.L. Linkage of a gene causing high bone mass to human chromosomel 1 (1 lql213) / M.L. Johnson, G. Gong, W. Kimberling // American J Human Genetic. 1997. — Vol. 60. — P. 1326−1332.
- Kaczur, V. The cystein-rich C-flanking region of the thyrothropin receptor has very ancient phylogenetic origins: implication from sequence analysis / Kaczur, V. Racz I, Szendroi A. et al. // J. Endocrine Genetic. 2002. — Vol. 3. — P. 46−54
- Kanis, J.A. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. 2008.
- Kim, D.J. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women / D.J. Kim, Y.H. Khang, J.M. Koh et al. // J. Clin. Endocrinol. 2006. — Vol. 64. — P.86−90.
- Klein J.R. Physiological relevance of thyroid stimulating hormone and thyroid stimulating hormone receptor in tissues other than the thyroid / Klein J.R. // J. Autoimmunity. 2003. — Vol. 36. — P. 417- 421.
- Klein, R.F. Regulation of bone mass in mice by the lipoxygenase gene Alox 15 / R.F. Klein, J. Allard, Z. Avnur // J. Science. 2004. — Vol. 303. — P. 229−232.
- Koay M.A. Genetic disorders of the LRP5-Wnt signaling pathway affecting the skeleton / M.A.Koay, M.A. Brown // TRENDS in Molecular Medicine. 2005. -Vol.11.-P. 129−137.
- Krolner, B. Spinal bone mineral content in myxoedema and thyrotoxicosis. Effect of thyroid hormones and antithyroid treatment / B. Krolner, J. Jorgensen, S. Nielsen // Clin. Endocrinol. 1983. — Vol. 18. — P. 439−446.
- Kumeda, Y. Persistent increase in bone turnover in Graves patients with subclinical hyperthyroidism / Y. Kumeda,, M. Inaba, H. J. Tahara et al. // Clinical Endocrinology and Metabolism. 2000. — Vol. 85. — P. 4157−4161.
- Kung A.W. A rat model of thyroid hormone-induced bone loss: effect of antiresoc})tive agents on regional bone density and osteocalcin gene expression / A.W. Kung, F. J. Ng // Thyroid. 1994. — Vol. 4. — P. 93−98.
- Kung, A. Bone mineral density in premenopausal women receiving long-term physiologocal doses of levothyroxine / A. Kung, K. Pun // JAMA. 1991. -Vol. 265.-P. 2688−2691.
- Kung, A. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin / A. Kung, S. Yeung //J. Clin. Endocrinol. Metab. 1996. -Vol. 81. — P. 1232−1236.
- Larijani, B. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women / B. Larijani, F. Gharibdoost, M .J. Pajouhi et al. // Clinical Pharmacy and Therapeutics. 2004. — Vol. 29. — P. 1−5.
- Lee, W.Y. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women / W.Y. Lee, K.W. Oh, E.J. Rhee et al. // J. Archives of Medical Research. 2006. — Vol. 37. — P. 511−516.
- Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer / L. A. Burmeister, M. O. Goumaz, C. N, Mariash et al. // J. Clin. Endocrinol. Metab. 1992. — Vol. 75. — P. 344−350.
- Levasseur, R. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders / R. Levasseur, D. Lacombe, M.C. Vernejoul // J. Joint Bone Spine. 2005. — Vol. 72. — P. 207−214.
- Liberopoulos, E. Impressive lipid changes following hypolipidaemic drug adminitration can unveil subclinical hyperthyroidism / E. Liberopoulos, G. Miltiadous, M. Elisaf // J. Diabetes Obesety Metabolism. 2001. — Vol. 3. — P. 9798.
- Lips, P. Epidemiology and predictors of fractures associated with osteoporosis / P. Lips // Am. J. Med. 1997. — Vol. 103. — P. 3S-8S.
- Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women / G. Pioli, M. Pedrazzoni, E. Palummeri et al. // Acta Endocrinol. 1992. — Vol. 126. — P. 238−242.
- Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules / E. Papini, L. Petrucci, R. Guglielmi et al. // J. Clin. Endocrinol. Metab. 1998. — Vol.83. — P. 780−783.
- Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women / T. Paul, J. Kerrigan, A. Kelly et al. // JAMA. -1988. -Vol. 259.-P. 3137−3141.
- Long-term thyroxine treatment and bone mineral density / J. Franklyn, J. Betteridge, J. Daykin et al. // Lancet. 1992. — Vol. 340. — P. 9−13.
- Low thyrotropin levels are not associated with bone loss in older women: a prospective study /D. C. Bauer, M. C Nevitt, B. Ettinger et al. // J. Clin. Endocrinol. Metab. 1997. — Vol. 82. — P. 2931−2936.
- Lupoli G.A. Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients / G.A. Lupoli, M.R.Fittipaldi, F. Fonderico et al. // Minerva Endocrinol. 2005. — Vol.30(2). — P.89−94.
- Majima T. Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease / T. Majima, Y. Komatsu, K. Doi et al. // J. Clin. Endocrinol. Metab. 2006. — Vol. 7. — p. 11 031 110.
- Manolagas, S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis / S.C. Manolagas // J. Endocrin. Rev. 2000. — Vol. 21. — P. 115−137.
- McDermott, M. T. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer / M. T. McDermott, J. J. Perloff, G. S. Kidd // Calcif. Tissue Int. 1995. — Vol. 56. — P. 521 525.
- Meier, C. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial / C. Meier, M. Beat, M. Guglielmetti et al. // J. Osteop. Internat. 2004. — Vol. 15. — P. 209−216.
- Melton, L.J. How many women have osteoporosis now? / L.J. Melton // J. Bone Mineral Research. 1995. — Vol. 10. — P. 175−177.
- Meunier, P. Hyperthyroidism and osteoporosis / P. Meunier // Ann. Endocrinol. 1995. — V. 56. — P. 57−59.
- Miura. M. A novel interaction between thyroid hormones and l, 25(OH)(2)D (3) in osteoclast formation / M. Miura, K. Tanaka, Y. Komatsu et al. // J. Biochemical and Biophysical Research Communications. 2002. — Vol. 291. -P. 987−994
- Morbidity in patients on L-thyroxine: a comprasion of those with a normal TSH to those with a suppressed TSH / G. Leese, R. Jung, C. Guthrie et al. // Clin. Endocrinol. 1992. — Vol. 37. — P. 500−503.
- Morris, M.S. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women /M.S. Morris // J. Bone. 2007. — Jan 19
- Mosekidle, L. Normal age-related changes in bone mass, structure and strength: consequences of the remodeling process / L. Mosekidle // Dan. Med. Bull. 1993.-Vol. 40.-P. 65−83.
- Mosekilde, L. Effects of thyroid hormones on bone and mineral metabolism / L. Mosekilde, E.F.Eriksen, P. Charles // J. Endocrin. and Metab. Clin. North America. 1990. — Vol. 19. — P. 35−63.
- Mudde, A.H. Is there a relationship between thyroid fimction and serum osteocalcin in women with multinodular goitre? A preliminary report. The Netherlands / A.H. Mudde, A. J. Bastiaanse, H. Jonkers // J. Medicine. 1990. -Vol. 37.-P. 17−20.
- Mudde, A.H. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism / A.H. Mudde, A.J. Houben, KAC Nieuwenhuijzen // J. Clinical Endocrinology (Oxford). 1994. — Vol. 41. — P. 421 424.
- Mudde, A. H. Peripheral bone density in women with untreated multinodular goitre / A. H. Mudde, F. J. Reijnders, A. C Kruseman // // Clin. Endocrinol. -1992.-Vol. 37 .-P. 35−39.
- Murakami, M. Thymic hyperplasia in patients with Graves disease. Identification of thyrotropin receptors in human thymus / M. Murakami, Y. Hosoi, T. Negishi // J. Clinical Investigation. 1996. — Vol. 98. — P. 2228−2234.
- Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism / M. S. Lee, S. Y. Kim, M.C. Lee et al.// J. Clin. Endocrinol. Metab. 1990. — Vol. 70. — P. 766−770.
- Noninvasive assessment of bone mineral and structure: state of the art / H. Genant, K. Engelke, T. Fuerst et al. // J. Bone Miner. Res. 1996. — Vol. 11. — P. 707−730.
- Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women / J. Faber, I. W. Jensen, L. Petersen et al. // Clin. Endocrinol. 1998. — Vol. 48. — P. 285 290.
- Norvack, D.V. TSH, the bone suppressing hormone / Norvack, D.V. J. // Cell.-2003.- Vol. 115.- P. 129−130
- Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorbtion / J. M. Britto, A. J. Fenton, W. R. Holloway et al.// Endocrinology. -1994,-Vol. 134.-P. 169−176.
- Pantazi, H. Changes in parameters o fb one and mineral metabolism during therapy for hyperthyroidism / H. Pantazi, P. Papapetrou // J. Clin. Endocrinol. Metab. 2000. — V. 85. — P. 1099−1106.
- Papi, G. A clinical and theraupeutic approach to thyrotoxicosis with thyroid-stimulating suppression only / G. Papi, E.N. Pearce, L.E. Braverman et al. // American J. Medicine. 2005. — Vol. 118. — P. 349−361.
- Persistent hyperactivity of the parathyroid glands in treated hypothyroid patients / R. Furlaneto, M. Castro, I. Kasamatsu et al.// Acta Endocrinol. 1991. -V. 123.-P. 609−612.
- Pearce E.N. Thyroid dysfunction in perimenopausal and postmenopausal women / E.N. Pearce // Menopause Int. 2007. — Vol. 13. -P.8−13.
- Pei, L. Fats loss is bones gain / L. Pei, P. Tontonoz // J. Clin. Invest. -2004.-Vol. 113.-P. 805−806.
- Pereira, R.C. Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts / R.C. Pereira, V. Jorgetti, E. Canalis // American J. Physiology. 1999. — Vol. 277. — P. E496-E504.
- Quan, M. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature / M. Quan, J. Pasieka, O. Rostad // J. Surg. Oncol. 2002. — Vol. 79. — P. 62−70.
- Real-time PCR provides evidence for thyrothropin receptor mRNA expression in orbital as well as in extraorbital tissues / P. Agretti, L. Chiovato, G. Marco, et al. // European J. Endocrinology. 2002. — Vol. 147. — P. 733−739.
- Reduced bone mineral in patients with eating disorders / K. Davies, P. Pearson, C Husemanetal.//Bone.-1990.-Vol. 11.-p. 143−147.
- Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone / P. Taelman, J. Kaufman, X. Janssens et al. // Clin. Endocrinol. 1990. -Vol. 33. -P. 107−117.
- Reid, I. Fat mass in an impotent determinant of whole body bone density in premenopausal women but not in men / I. Reid, L. Plank, M. Evans // J. Clin. Endocrinol. Metab. 1992. — Vol. 75. — P. 779−782.
- Reproductive factors and fatal hip fractures. A Norwegian prospective study of 63 000 women / B. Jacobsen, S. Nilssen, I. Heuch et al. // J. Epidemiol, and Community Health. 1998. — Vol. 52. — P. 645−650.
- Retrosternal goitre with subclinical hyperthyroidism presenting with trochanteric fracture / S. Mukhopadhyay, T. J. Satpathi // Assoc Physicians India. 2010. — Vol. 58. -p.502−504.
- Ridgway, E. C. Medical treatment of benign thyroid nodules: have we defined a benefit? / E. C. Ridgway // Ann. Intern. Med. 1998. — Vol. 128. — P. 403 405.
- Risk factors for hip fracture in Asian men and women: The Asian osteoporosis Study / E. Lan, P. Suriwongpaisal, J. Lee et al. // J. Bone Miner. Res. -2001. -V. 16.-P. 572−580.
- Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group / S. R. Cummings, M. C. Nevitt, W. S. Browner et al. // N. Engl. J. Med. 1995. — Vol. 332. — P. 767−773.
- Risk for fracture in women with low serum levels of thyroid-stimulating hormone / D. Bauer, B. Ettinger, M. Nevitt et al. // Ann. Intern. Med. 2001. -Vol. 134.-P. 561−568.
- Rosen, C J. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism / C.J. Rosen, R. A. Adler // J. Clin. Endocrinol. Metab.- 1992,-Vol. 75 .-P. 1531−1534.
- Ross D.S. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease / Ross D.S. // J. Endocrinol. Metab. Clin. North America. 2001. — Vol. 30. — P. 245−264.
- Ross, D. S. Hyperthyroidism, thyriod hormone therapy and bone / D. S. Ross // Thyroid. 1994. — Vol. 4. — P. 319−326.
- Ross, D. S. Subclinical thyrotoxicosis / D. S. Ross // Adv. Endocrinol. Metab. -1991.-Vol. 2. -P. 89−105.
- Salto, C. Ablation of TRa and a concomitant overexpression of a 1 yields a mixed hypo and hyperthyroid phenotype in mice / C. Salto, J.M. Kindblom, C. Johansson et al. // J. Molecular Endocrinology, 2001, Vol. 15, pp. 2115−2128
- Saito J. Osteoporosis treatment in patients with hyperthyroidism / J Saito, T. Nishikawa // Nihon Rinsho. 2009. — Vol. 67. — P. 1011−1016.
- Secondary contributors to bone loss in osteoporosis related hip fractures / B.J. Edwardsi C.B. Langman., A.D. Bunta et al. // Osteoporos Int. 2008. — Vol. 19.-p. 991−999.
- Sellitti, D.F. Differential expression of thyrotropin receptor mRNA in the porcine heart / D.F. Sellitti, R. Hill, S.Q. Doi, // J. Thyroid. 1997. — Vol. 7. — P. 641−646.
- Sellitti, D.F. Renal expression of two «thyroid-specific» genes: thyrotropin receptor and thyroglobulin / D.F. Sellitti, T. Akamizu, S.Q. Doiet al. // J. Experimental Nephrology. 2000.- Vol.8. — P. 235−243.
- Siddiqi, A. Tri-iodothyronin regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells / A. Siddiqi, J.M. Burrin, D.F. Wood et al. // J. Endocrinology. 1998. — Vol. 157. — P. 453 461
- Simsek, G. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism- changes as a result of reversal to euthyroidism / Simsek,
- G. Y. Karter, S. Aydin et al. //Chynese J. Physiology. 2003.- Vol. 46. — P. 181 186
- Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine / C Marcocci, F. Golia, E. Vignali et al. // J. Bone Miner. Res. 1997. -Vol. 12. — 72−77.
- Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy / S. L. Greenspan, F. S. Greenspan, N. M. Resnick et al. // Am. J. Med. 1991. — Vol. 91. — P. 5−14.
- Solomon, B. L. Prevalence of fractures in postmenopausal women with thyroid disease / B. L. Solomon, L. Wartofsky, K. D. Burman // Thyriod. 1993. -Vol.3 .-P. 17−23.
- Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis / F. Hawkins, D. Rigopoulou, K. Papapietro et al. // Calcif. Tissue Int. 1994. -Vol. 54 .P. 16−19.
- Spitzweg, C. Expression of thyroid-related genes in human thymus / C. Spitzweg, W. Joba, A.E. Heufelder // J. Thyroid. 1999. — Vol. 9. — P. 133−141
- Stephan, J. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment / J. Stephan, Z. Lemanova // Bone Miner. 1992. -Vol. 17.-P. 377−388.
- Stevens, D.A. Thyroid hormone activates fibroblast growth factor receptor 1 in bone / D.A. Stevens, C.B. Harvey, A.J. Scott J. et al. // Molecular Endocrinology. 2003.- Vol. 17.- P. 1751−1766.
- Svare A. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study /A. Svare, T.I.Nilsen, T. Biovo // Eur. J. Endocrinol. 2009. -V.161(5). — P.779−786.
- Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine / D. S. Ross, R. M. Neer, E. Ridgway et al. // Am. J. Med. 1987. — Vol. 82. — P. 1167−1170.
- Suppression of serum TSH by GravesTg: evidence for a functional pituitary TSH receptor / L.J. Brokken, J.W. Scheenhart, W.M. Wiersinga // J. Clinical Endocrinology and Metabolism. 2001. — Vol. 86. — P. 4814−4817
- Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis / D. J. Grant, M. E. McMurdo, P.A. Mole et al. // Clin. Endocrinol. 1993. — Vol. 39. — P. 529−533.
- Surks, M.I. Subclinical thyroid disease. Scientific review and guidelines and management / M.I. Surks, E. Ortiz, G.H. Daniels // J. American Medical Assosciation. 2004. — Vol. 291. — P. 228−238.
- Takeuchi Y. Secondary osteoporosis UPDATE. How to diagnose secondary osteoporosis and disorders presenting low bone mineral density / Y. Takeuchi Y // Clin. Calcium. -2010. Vol. 5. — p. 665−71.
- The effects of triodthyronine of bone metabolism in healthy ambulatory men / S. Smith, J. Lovejoy, J. Rood et al. // Thyroid 2003. — Vol. 13. — P. 357−364.
- The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism / T. Vadiveloo, P.T. Donnan, L.J.Cochrane et al. // Clin. Endocrinol. Metab. 2011. — Vol. — 5. — P. 1344−1351.
- The spectrum of thyroid disease in a community: the Whickham survey / W. M. Tunbridge, D. C. Evered, R. Hall et al. // Clin. Endocrinol. 1977. — Vol. 7. -P. 481−493.
- Therapy with parenteral pamidronate prevents thyroid hormone induced bone turnover in humans / H. Rosen, A. Moses, C. Gundberg et al. // J. Clin. Endocrinol. Metab. 1993. — Vol. 77. — P. 664−669.
- The role of FSH and TSH in bone loss and its clinical relevance / M. Agrawal, G. Zhu, L. Sun et al. // Curr. Osteoporos Rep. 2010. — V.8(4). — P.205−211.
- Thyroid hormone use and the risk of hip fracture in women > 65 years: a case- control study / S. Van Den Eeden, J. Barzilay, B. Ettinger et al. // Women Health. -2003.-V. 12.-P. 27−31.
- Thyrotoxic bone disease in women: a potentially reversible disorder / T. Diamond, J. Vine, R. Smart et al. // Ann. Intern. Med. 1994. — Vol. 120. — P. 8−11.
- Thyrotropin receptor expression in Graves orbital adipose connective tissues: potential autoantigen in Graves ophthalmopathy / R.S. Bahn, C.M. Dutton, N. Natt et al. // J. Clinical Endocrinology and Metabolism. 1998. — Vol. 83. — P. 998−1002.
- Toft, A. Clinical practice: Subclinical hyperthyroidism / A. Toft // N. Engl. J. Med.-2001.-V. 345. P. 512−516.
- Toft, A. Thyroxine replacement therapy / A. Toft // Clin. Endocrinol. 1991. -Vol. 34.-P. 103−105.
- Toh, S. H. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study / S. H. Toh, P. H. Brown // J. Bone Miner. Res. -1990.-Vol. 5. P. 463−467.
- Toh, S. H. Effects of hyperthyroidism and its treatment on bone mineral content /S. H. Toh, В. С Claunch, P. H. Brown // Arch. Intern. Med. 1985. -Vol. 145.-P. 883−886.
- Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standarts of Care Committee, American Thyroid Association / P. A. Singer, D. S. Cooper, E. G. Levy et al. // JAMA. 1995. — Vol. 273. — P. 808−812.
- TSH is a negative regulator of skeletal remodeling / E. Abe, R.C. Marians, W. Yu.//J. Cell.-2003.-Vol. 115.-P. 151−162.
- Tudor-Locke, C Factors related to variation in premenopausal bone mineral status: a health promotion approach / C Tudor-Locke, R. McCole // Osteoporosis Int .-2000.-V. 11.-P. 1−24.
- Urinary excretion of pyridinoline and deoxypyridinoline measured by immunoassay in hypothyroidism / H. Nakamura, T. Mori, R. Genta et al. // Clin. Endocrinol. 1996. -V. 44. — P. 447−451.
- Usefulness of quantative ultrasound for early detection of bone mass change / H. Park, D. Kim, C Ahn et al. // Bone. 2001. — V. 28. — P. 183.
- Vestergaard, P. Hyperthyroidism, bone mineral and fracture risk a metaanalysis / P. Vestergaard, L. Mosekiide // Thyroid. — 2003. — Vol. 13.- P. 585 593.
- Vestegaard, P. Hyperthyroidism, bone mineral and fracture risk a metaanalysis / P. Vestegaard, Mosekiide L. // J. Thyroid. 2003. — Vol. 13. — P. 585 593.
- Vestergaard P. Mosekiide L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16 249 patients / Vestergaard, P. Mosekiide L. // J. Thyroid. 2002. — Vol. 12. — P. 411−419.
- Wakita R. Thyroid hormone-induced chondrocyte terminal differentiation in rat femur organ culture / R. Wakita, T. Izumi, M. Itoman // Cell and Tissue Res. -1998.-Vol. 293.-P. 357−364.
- Wawschinek O., Eber O., Petek W. Bestimmung der Hamjodausscheidung mittels einer modifizierten Cer-Arsenitmethode / O. Wawschinek, O. Eber, W Petek. // Ber. OGKC. 1985. — N.8 — p.13−15.
- Wartofsky, L. Does replacement L-thyroxine therapy cause osteoporosis // Adv. Endocrinol. Mol. Metab. 1993. — Vol. 4. — P. 157−175.
- Wiersinga, W. Should we treat mild subclinical/mild hyperthyroidism? Yes.
- W. Wiersinga // Neth. J. Med. 2011. — Vol. 22. — P.324 -329.
- Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-Iike cells / J.A. Tsai, A. Janson, E. Bucht et al. // J. Calcified Tissue International. 2004.- Vol.74. — P. 486−491.
- Williams G.R. Actions of thyroid hormones in bone /G.R. Williams // Endokrynol. Pol. 2009. — Vol. 5. — p. 380−388.
- Wilson, G.R. Subclinical thyroid disease / G.R. Wilson, R. W Curry // J. American Family Physician. 2005. — Vol. 72. — P. 1517−1524.
- Zaidi M. Thyroid-stimulating hormone, thyroid hormones, and bone loss / M. Zaidi T.F. Davies, A. Zallone et al. // Curr. Osteoporos. Rep. 2009. — V.7(2). -P.47−52.
- Zaidi M. Paradigm shift in the pathophysiology of postmenopausal and thyrotoxic osteoporosis / M. Zaidi, J. Igbal, H.C.Blair et al. // Mt. Sinai J. Med. -2009. V.76(5). — P.474−483.
- Zatonska, K. The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis / K. Zatonska, M. Bolanowski // Pol. Merkuriusz. Lek. 2000. -V. 8. -P. 356−359.
- Zhang, Y. Changes of growth hormone in patient with hyperthyroidism complicated by osteoporosis / Y. Zhang, S. Guo // Bone. 2001. — V. 28. — P. 192 193.